Production (Stage)
Acrivon Therapeutics, Inc.
ACRV
$1.17
$0.021.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.80% | -1.74% | -19.38% | -14.02% | 14.37% |
| Total Depreciation and Amortization | 2.64% | 20.72% | 10.09% | 1.79% | 50.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.50% | 12.95% | 0.26% | -9.86% | 16.29% |
| Change in Net Operating Assets | -281.80% | -2.26% | 9.79% | 151.71% | -191.52% |
| Cash from Operations | -12.53% | -0.21% | -24.60% | 18.61% | -38.14% |
| Capital Expenditure | 92.99% | 16.38% | -621.90% | 83.19% | 29.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 26.46% | -10.36% | 119.34% | -1,418.93% | -69.27% |
| Cash from Investing | 33.32% | -9.99% | 118.19% | -1,605.03% | -71.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | 88,517.72% | -75.16% |
| Repurchase of Common Stock | 46.83% | 45.95% | -134.71% | -207.23% | 87.20% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -100.57% | 63,455.29% | 91.76% |
| Cash from Financing | 46.99% | 56.98% | -101.22% | 71,815.12% | 91.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 81.53% | -27.66% | -113.16% | 287.66% | -285.18% |